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Abstract
Activation of androgen receptor (AR) may play a role in the development of castration resistant 
prostate cancer. Two intracellular tyrosine kinases, Ack1 (activated cdc42-associated kinase) and 
Src, phosphorylate and enhance AR activity and promote prostate xenograft tumor growth in 
castrated animals. However, the upstream signals that activate these kinases and lead to AR 
activation are incompletely characterized. In this study, we investigated AR phosphorylation in 
response to non-androgen ligand stimulation using phospho-specific antibodies. Treatment of 
LNCaP and LAPC-4 cells with epidermal growth factor (EGF), heregulin, Gas6 (ligand binding to 
Mer receptor tyrosine kinase and activating Ack1 downstream), interleukin (IL)-6 or bombesin 
stimulated cell proliferation in the absence of androgen. Treatment of LNCaP and LAPC-4 cells 
with EGF, heregulin, or Gas6 induced AR phosphorylation at Tyr-267; IL-6 or bombesin 
treatment did not. AR phosphorylation at Tyr-534 was induced by treatment with EGF, IL-6 or 
bombesin, but not by heregulin or Gas6. siRNA-mediated knockdown of Ack1 or Src showed that 
Ack1 mediates heregulin- and Gas6-induced AR Tyr-267 phosphorylation whereas Src mediates 
Tyr-534 phosphorylation induced by EGF, IL-6, and bombesin. Dasatinib, a Src inhibitor, blocked 
EGF-induced Tyr-534 phosphorylation. In addition, we show dasatinib also inhibited Ack1 kinase. 
Dasatinib inhibited heregulin-induced Ack1 kinase activity and AR Tyr-267 phosphorylation. 
Dasatinib inhibited heregulin-induced AR-dependent reporter activity. Dasatinib also inhibited 
heregulin-induced expression of endogenous AR target genes. Dasatinib inhibited Ack1-
dependent colony formation and prostate xenograft tumor growth in castrated mice. Interestingly, 
Ack1 or Src knockdown or dasatinib did not inhibit EGF-induced AR Tyr-267 phosphorylation or 
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EGF-stimulated AR activity, suggesting the existence of an additional tyrosine kinase that 
phosphorylates AR at Tyr-267. These data suggest that specific tyrosine kinases phosphorylate AR 
at distinct sites and that dasatinib may exert anti-tumor activity in prostate cancer through 
inhibition of Ack1.
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Introduction
Androgen deprivation therapy through surgical or medical castration is commonly used as a 
systemic therapy of advanced prostate cancer because it is initially effective in causing 
tumor regression and palliating cancer-related symptoms. However, virtually all patients 
eventually progress and develop hormone refractory prostate cancer or castration resistant 
prostate cancer (CRPC), a terminal disease with poor prognosis. Substantial evidence 
indicates that androgen receptor (AR) activation in the environment of low circulating 
testosterone plays a critical role in the development of CRPC. Studies using xenograft tumor 
models demonstrate that prostate xenograft tumors that recur following castration express 
AR-dependent genes (Gregory et al 1998). In these cells, the AR protein is stabilized and 
constitutively localized to the nucleus and is hypersensitive to low levels of androgen 
(Gregory et al 2001). Overexpression of AR enhanced the ability of androgen-dependent 
prostate xenografts to form tumor in castrated animals while knockdown of AR inhibited 
their tumorigenicity (Chen et al 2004). Multiple mechanisms have been shown to activate 
AR in CRPC. These include AR gene amplification, increased AR expression, AR point 
mutations frequently occurring in the ligand binding domain that broaden ligand specificity, 
overexpression of AR coactivators, and intratumoral production of androgen (Scher and 
Sawyers 2005).
In addition to these mechanisms, AR may be activated by crosstalk with signaling pathways 
initiated by cell surface receptors binding to growth factors, cytokines, and neuropeptides. 
Intracellular pathways involving mitogen activated protein kinase (MAPK) or 
phosphatidylinositol 3-kinase/Akt have been proposed to mediate activation of AR 
downstream of receptor tyrosine kinases (Gregory et al 2004, Wang et al 2007). For 
example, epidermal growth factor (EGF) receptor enhances AR transcriptional activity 
through increasing the interaction between AR and the steroid receptor coactivator TIF2 
secondary to MAPK-dependent phosphorylation of TIF2 (Gregory et al 2004). HER-2 
(ErbB2) activates the AR transcriptional function by increasing protein stability, recruitment 
and DNA binding (Liu et al 2005, Mellinghoff et al 2004). AR protein is phosphorylated at 
multiple serine/threonine residues and phosphorylation at some of these sites has been 
proposed to regulate nuclear localization and export (Gioeli et al 2002, Gioeli et al 2006, 
Ponguta et al 2008). Recently, several groups reported that tyrosine phosphorylation of AR 
protein by nonreceptor tyrosine kinases Src and Ack1 (activated cdc42-associated kinase) 
may play a role in AR activation in the low androgen environment, thereby promoting the 
development of CRPC (Guo et al 2006, Kraus et al 2006, Mahajan et al 2007). Src-mediated 
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phosphorylation of AR at Tyr-534 resulted in activation of AR and nuclear translocation and 
DNA binding in the absence of androgen (Guo et al 2006, Kraus et al 2006). Our previous 
work identified Ack1 as a protein activated downstream of Mer receptor tyrosine kinase in 
prostate cancer cells (Mahajan et al 2005). Furthermore, we demonstrated that expression of 
activated Ack1 increased prostate xenograft tumor growth in castrated animals as well as 
AR target gene expression and AR recruitment to the enhancers of target genes at 
suboptimal androgen concentrations (Mahajan et al 2007). Ack1 interacted with and 
phosphorylated AR protein at Tyr-267 and Ack1 was shown to be required for optimal AR 
target gene expression and AR recruitment. Tyrosine phosphorylated AR protein was 
expressed in 8 out of 18 primary CRPC tumor samples and its expression was correlated 
with Ack1 activation in the same tumors. In this report, we investigate the upstream signals 
activating AR phosphorylation and we show that Src and Ack1 kinases each contribute to 
site-specific phosphorylation of AR.
Results
Site-specific phosphorylation of androgen receptor by Ack1 and Src kinases
Previous reports demonstrated that AR protein may be phosphorylated at Tyr-534 or 
Tyr-267 residues (Guo et al 2006, Kraus et al 2006, Mahajan et al 2007). To elucidate 
signaling pathways leading to AR tyrosine phosphorylation, phospho-specific antibodies 
against AR protein phosphorylated at these residues were generated. Their specificity was 
tested against wildtype and phosphorylation-site mutant AR. Wildtype AR, Y267F AR, or 
Y534F AR expression vectors were co-transfected along with the activated Ack1 or 
activated Src kinase expression vector. The phospho-Y267 specific antibody detected AR 
only when Ack1 was co-expressed and did not detect the AR Y267F mutant protein in cell 
lysates co-expressing Ack1 (Fig. 1A). The phospho-Y534 specific antibody detected AR 
only when Src was co-expressed and did not recognize the AR Y534F mutant protein in the 
presence of Src (Fig. 1B). Co-expression of Ack1 led to phosphorylation of Tyr-267 but not 
Tyr-534 of AR. Conversely, co-expression of Src resulted in phosphorylation of Tyr-534 but 
not Tyr-267 of AR. These data suggest that Ack1- and Src-mediated phosphorylation of AR 
is site-specific (i.e. Ack1 targets Tyr-267 but not Tyr-534 and vice versa for Src).
Phosphorylation of androgen receptor by ligand stimulation
Tyrosine phosphorylation of endogenous AR in prostate cancer cells induced by physiologic 
ligand stimulation was characterized using the phospho-specific antibodies. Extracellular 
ligands that bind to the cell surface receptors and have previously been reported to enhance 
AR activity or may potentially enhance AR activity were tested for their ability to induce 
AR tyrosine phosphorylation. Gas6 is the ligand for Mer receptor tyrosine kinase, which we 
have previously shown to activate Ack1 in prostate cells (Mahajan et al 2005). Heregulin 
binds to HER-3 and activates HER-2 kinase through the formation of the HER-2/HER-3 
heterodimer. Bombesin (also known as gastrin-releasing peptide) is a neuropeptide produced 
by neuroendocrine cells, which has been reported to support growth of androgen-dependent 
LNCaP cells in an androgen-depleted condition through Src-mediated activation of AR 
(Desai et al 2006, Gong et al 2006, Yang et al 2009). Interleukin-6 leads to ligand-
independent activation of the AR N-terminal domain that involves MAPK and steroid 
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receptor coactivator-1 (Ueda et al 2002b). Treatment of LNCaP cells with EGF, heregulin, 
or Gas6 induced phosphorylation of the AR protein at Tyr-267 (Fig. 1C). AR 
phosphorylation was transient and peaked at 60-90 min. and returned to the basal level by 4 
hrs (data not shown). Treatment with IL-6 or bombesin did not induce phosphorylation of 
the AR at Tyr-267. Phosphorylation of the AR at Tyr-534 was induced by treatment with 
EGF, IL-6 or bombesin, but not with heregulin or Gas6 (Fig. 1D). EGF was the only ligand 
tested that induced AR phosphorylation at both Tyr-267 and Tyr-534 sites, in contrast to 
other ligands that produced site-specific AR phosphorylation (i.e. heregulin and Gas6 at 
Tyr-267 and IL-6 and bombesin at Tyr-534). LAPC-4 prostate cancer cells that express 
wildtype AR endogenously (Klein et al 1997) were treated with these ligands and AR 
phosphorylation at Tyr-267 and Tyr-534 sites was analyzed similarly. LAPC-4 cells 
exhibited the same pattern of AR phosphorylation by these ligands as LNCaP cells 
(Supplementary Fig. 1).
Stimulation of cell proliferation by non-androgen ligands
Since cell proliferation requires AR activation in androgen-dependent prostate cancer cells, 
the effect of these ligands inducing AR phosphorylation on cell proliferation was 
determined. In LNCaP cells, treatment with EGF, heregulin, Gas6, bombesin, or IL-6 all 
stimulated cell proliferation to similar levels as the androgen dihydrotestosterone (DHT) 
(Fig. 2). In LAPC-4 cells, all ligands stimulated cell proliferation although Gas6 and IL-6 
were less effective than DHT or other ligands. These results are in agreement with previous 
reports of stimulation of proliferation in the absence of androgen by heregulin (Gregory et al 
2005), bombesin (Desai et al 2006, Lee et al 2001), or IL-6 (Ueda et al 2002a). These data 
demonstrate that these non-androgen ligands inducing AR phosphorylation promote prostate 
cancer cell proliferation in the absence of androgen.
Dasatinib inhibits Ack1 kinase activity but does not inhibit EGF-induced AR 
phosphorylation at Tyr-267
For characterization of signaling pathways and therapeutic applications, a small molecule 
kinase inhibitor of Ack1 would be desirable. A previous report indicated that dasatinib, a 
potent inhibitor of Src and Abl kinases, interacted with several additional tyrosine kinases in 
a competition binding assay, including Ack1 (Carter et al 2005). The ability of dasatinib to 
inhibit Ack1 autophosphorylation as a marker of kinase activity was tested in 293T cells 
transfected to express activated Ack1 (Fig. 3A). Dasatinib inhibited Ack1 
autophosphorylation in a dose dependent manner, with dasatinib doses of 10 nM or greater 
demonstrating nearly complete inhibition of Ack1 phosphorylation, consistent with the 
previously reported Kd of 6 nM (Carter et al 2005). Treatment of LNCaP cells with 
dasatinib inhibited heregulin-induced Ack1 phosphorylation almost completely at doses of 
10 nM or greater (Fig. 3B). Dasatinib treatment inhibited heregulin-induced AR 
phosphorylation at Tyr-267. The concentration of dasatinib required for inhibition of AR 
phosphorylation at Tyr-267 was similar to that for inhibition of heregulin-induced Ack1. 
This result is consistent with the notion that heregulin-induced activation of Ack1 mediates 
AR phosphorylation at Tyr-267. The effect of dasatinib on EGF-induced phosphorylation of 
AR was tested. EGF-induced AR phosphorylation at Tyr-534 was inhibited by dasatinib 
(Fig. 4A). Since dasatinib inhibits Src, this finding is consistent with the idea that Src 
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activation downstream of EGF receptor leads to AR phosphorylation at Tyr-534. Dasatinib 
had no effect on EGF-induced AR phosphorylation at Tyr-267, even at doses as high as 
1000 nM (Fig. 4B). However, Src activation after EGF treatment was inhibited by dasatinib 
at a dose as low as 1 nM (Fig. 4D). In LNCaP cells, Ack1 was not activated after EGF 
treatment while heregulin-induced Ack1 activation was detected (Fig. 4C). These results 
suggest that at least one other tyrosine kinase (other than Src and Ack1) mediates AR 
phosphorylation at Tyr-267 after EGF treatment in LNCaP cells and that this kinase (or 
kinases) is insensitive to dasatinib.
Role of Ack1 and Src in ligand-stimulated AR phosphorylation
To investigate more directly the role of Ack1 or Src in AR phosphorylation after ligand 
stimulation, the effect of Ack1 or Src knockdown by siRNA was tested (Fig. 5). Ack1 
knockdown inhibited AR phosphorylation at Tyr-267 induced by heregulin or Gas6 
treatment. Src knockdown inhibited AR phosphorylation at Tyr-534 induced by EGF or IL-6 
or bombesin treatment. However, EGF-induced AR phosphorylation at Tyr-267 was not 
inhibited by Ack1 knockdown or Src knockdown, despite markedly reduced expression 
levels of Ack1 or Src by siRNA confirmed by immunoblotting. These data suggest that 
downstream of cell surface receptors, Ack1 mediates AR tyrosine phosphorylation at 
Tyr-267 and Src mediates AR tyrosine phosphorylation at Tyr-534. However, EGF-induced 
AR phosphorylation at Tyr-267 likely involves an additional kinase(s) that is not inhibited 
by dasatinib.
Effect of dasatinib on Ack1-induced AR activation
The biological effect of dasatinib on prostate cancer cells was investigated. First, LNCaP 
cells transfected with the AR-dependent reporter ARR2-PB-luciferase were investigated. 
Treatment of these cells with heregulin or EGF (without androgen) increased luciferase 
activity. AR antagonist bicalutamide inhibited androgen-induced AR reporter activity but 
did not inhibit heregulin- or EGF-induced AR reporter activity (Supplementary Fig. 2). 
Therefore, heregulin- or EGF-induced AR activation likely reflects ligand-independent 
activation of AR via receptor tyrosine kinase-mediated pathways. Dasatinib treatment 
inhibited heregulin-induced AR reporter activity with the IC50 of 4.9 nM, consistent with 
the hypothesis that the stimulatory effect of heregulin is mediated by downstream Ack1 
activation (Fig. 6A). However, dasatinib treatment had no effect on EGF-induced AR 
reporter activity, even at doses as high as 1000 nM, in contrast to its inhibitory effect on 
heregulin-mediated AR reporter activity (Fig. 6B). The effect of dasatinib on expression of 
endogenous AR target genes prostate specific antigen (PSA) and human kallikrein 2 (hK2) 
(also known as KLK2) was tested. Treatment of LNCaP cells with EGF or heregulin 
increased PSA and hK2 mRNA levels by 4-6 fold. Dasatinib treatment partially blocked 
heregulin-induced expression of PSA and hK2 mRNA but not EGF-induced expression of 
PSA and hK2 mRNA (Fig. 6C and D). Similar results were seen in LAPC-4 cells 
(Supplementary Fig. 3). Since heregulin-induced Tyr-267 phosphorylation is blocked by 
dasatinib, but EGF-induced Tyr-267 phosphorylation is not blocked by dasatinib, these 
results suggest that the stimulatory effect of growth factors on AR is correlated with 
induction of Tyr-267 phosphorylation, either by Ack1 or an unidentified tyrosine kinase 
downstream of EGF.
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Effect of dasatinib on Ack1-induced colony formation and xenograft tumor growth
Activated Ack1 enhances the ability of LNCaP cells to form colonies in soft agar and grow 
as subcutaneous xenograft tumor in castrated mice (Mahajan et al 2005, Mahajan et al 
2007). The effect of dasatinib on Ack1-induced colony formation was determined. Dasatinib 
treatment decreased the number of soft agar colonies in LNCaP cells expressing activated 
Ack1 in a dose-dependent manner (Fig. 7A). Dasatinib also inhibited soft agar colony 
growth of LNCaP vector control cells, likely through inhibition of Src kinase expressed in 
LNCaP (Park et al 2008). We investigated the effect of dasatinib treatment in vivo on the 
xenograft tumor growth of LNCaP-Ack1 cells in castrated mice. Castrated mice with 
xenograft tumors were treated with dasatinib orally or vehicle control and the tumor volume 
was monitored. Administration of dasatinib resulted in significant inhibition of xenograft 
tumor growth. At day 25 and 29, the tumor volume of the dasatinib treatment group was 
decreased by approximately 50% compared to the tumor volume of the control group (Fig. 
7B). The phosphorylation status of Ack1 and AR proteins was determined by 
immunoblotting of protein extracts of harvested tumor tissues at the conclusion of the 
experiment. In tumors harvested from control animals, Ack1 and AR at Tyr-267 were 
constitutively phosphorylated, whereas in tumors from dasatinib treated animals, Ack1 and 
AR proteins were not phosphorylated (Fig. 7C). These data suggest that inhibition of Ack1 
kinase by dasatinib leads to loss of AR phosphorylation and decreased xenograft tumor 
growth.
Discussion
In this report, we demonstrate that Ack1 and Src tyrosine kinases target distinct AR 
phosphorylation sites (i.e. Tyr-267 by Ack1 and Tyr-534 by Src) after activation by cell 
surface receptors. EGF, IL-6, and bombesin-induced AR phosphorylation at Tyr-534 was 
inhibited by Src knockdown and dasatinib, a potent Src inhibitor, suggesting Src 
involvement downstream of these ligands. Activation of AR by EGF and bombesin through 
Src had been reported previously (Desai et al 2006, Guo et al 2006, Kraus et al 2006). A 
recent report indicated that the neuroendocrine-derived peptide parathyroid hormone-related 
protein stabilizes AR by reducing interaction with the ubiquitin ligase CHIP through Src-
mediated phosphorylation of AR at Tyr-534 (DaSilva et al 2009). Involvement of Ack1 
downstream of heregulin and Gas6 in AR phosphorylation at Tyr-267 was confirmed by 
Ack1 knockdown as well as dasatinib, which has been shown to be an inhibitor of Ack1 in 
this work. However, inhibition of Src and Ack1 did not prevent EGF-induced AR tyrosine 
phosphorylation at Tyr-267, suggesting the existence of an additional unidentified tyrosine 
kinase (or kinases) capable of phosphorylating AR at Tyr-267 (Fig. 8). Although 
identification and understanding the functional role of this kinase on AR signaling will 
require further work, it is clear that Tyr-267 phosphorylation is involved in some modes of 
AR transactivation no matter which tyrosine kinase is involved. Inhibition of growth factor-
induced AR activity by dasatinib correlates with loss of AR phosphorylation at Tyr-267, as 
dasatinib inhibits heregulin-induced AR Tyr-267 phosphorylation and AR reporter activity 
and target gene expression. In contrast, EGF-induced AR Tyr-267 phosphorylation and AR 
reporter activity and target gene expression are resistant to dasatinib. This result raises a 
Liu et al. Page 6













possibility that phosphorylation of Tyr-267 is required for AR activation downstream of 
receptor tyrosine kinases.
The functional consequences of AR phosphorylation at Tyr-267 and Tyr-534 appear similar 
in that phosphorylation at both sites has been linked to enhanced AR recruitment and 
expression of AR target genes at suboptimal androgen concentrations (Guo et al 2006, 
Mahajan et al 2007). However, chromatin immunoprecipitation analysis demonstrated that 
Src-induced AR activation involves AR recruitment preferentially to the proximal promoter 
elements of the canonical target gene prostate specific antigen and that there is no increase 
in the binding of AR to the distal enhancer where androgen-induced and Ack1-driven AR 
recruitment takes place (Desai et al 2006, Mahajan et al 2007, Yang et al 2009). Whether 
this difference in the AR recruitment sites stems from the distinct AR phosphorylation sites 
or possibly due to other components of the transcriptional complex regulated by these 
kinases is unclear. The differential effect of AR phosphorylation sites on target gene 
expression and binding of coactivators and corepressors and other proteins involved in the 
assembly of the active transcriptional complex requires further elucidation.
Dasatinib inhibits a wide spectrum of kinases such as Abl and Src and its ability to inhibit 
Bcr-Abl kinase (unmutated and mutated forms) led its approval for treatment of imatinib-
resistant chronic myelogenous leukemia (Brave et al 2008). In addition to the ability of Src 
to promotes castration resistant progression and AR activation, Src is involved in regulating 
prostate cancer cell migration, invasion, and metastasis and affects bone remodeling (Araujo 
and Logothetis 2009, Park et al 2008). Therefore, dasatinib is currently being studied in 
treatment of CRPC as a single agent and in combination with docetaxel chemotherapy 
(Araujo et al 2009, Yu et al 2009). Our data show that Ack1 kinase is inhibited by dasatinib 
at clinically relevant concentrations, and preclinical xenograft studies demonstrate the 
feasibility of inhibiting Ack1 in vivo as tumors exhibit loss of constitutive Ack1 and AR 
phosphorylation after oral treatment with dasatinib. This raises a possibility that dasatinib 
may have clinical activity against Ack1-driven malignancies. Ack1 binds and is activated by 
several receptor tyrosine kinases such as EGFR, HER-2, Mer, Axl, platelet derived growth 
factor receptor, LTK (leucocyte receptor tyrosine kinase belonging to the insulin receptor 
family) and ALK (anaplastic lymphoma kinase) (Galisteo et al 2006, Mahajan et al 2005, 
Pao-Chun et al 2009). A recent study demonstrated that the Ack1 gene is amplified and 
overexpressed in several tumor types, including castration resistant prostate cancer, and this 
was correlated with cancer progression and poor prognosis (van der Horst et al 2005). 
Additionally, Ack1 may also be activated by oncogenic mutations. The current release 
(version 42) of the Catalogue of Somatic Mutation in Cancer database reported 5 out of 229 
tumor samples containing point mutations in Ack1, some of which are likely to lead to 
constitutive activation of kinase (Forbes et al 2006). In a subset of primary CRPC tumor 
specimens (8 out of 18), expression of tyrosine-phosphorylated AR and Ack1 was detected 
by immunoprecipitation and immunoblotting of tumor lysates (Mahajan et al 2007). Our 
findings provide additional mechanisms by which dasatinib may exert anti-tumor activity in 
CRPC. Although both Src and Ack1 phosphorylate AR protein, they target distinct sites. 
Therefore, phospho-Tyr-267 and phospho-Tyr-534 AR expression in CRPC tumors may 
serve as a predictive biomarker of tyrosine kinase inhibitor therapy.
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LNCaP cells were obtained from the American Type Culture Collection (Manassas, VA). 
LAPC-4 cells were provided by Dr. Charles Sawyers (Klein et al 1997). EGF (R&D 
Systems, Minneapolis, MN), IL-6 (R&D), Gas6 (R&D), and bombesin (Sigma-Aldrich, St. 
Louis, MO) were purchased. Heregulin was a gift from Genentech (South San Francisco, 
CA). Dasatinib was obtained from Bristol-Myers-Squibb (Princeton, NJ). Phospho-specific 
polyclonal antibody against Tyr-267 of AR was generated by a commercial vendor (21st 
Century Biochemicals, Marlboro, MA). Rabbits were immunized with carrier-conjugated 
phospho-peptides spanning Tyr-267. Immunodepletion using a nonphospho-peptide column 
and affinity purification using the phospho-peptide column were performed by the vendor. 
Phospho-specific antibody against Tyr-534 of AR was raised in rabbits using standard 
methods and affinity purified in a similar fashion; its characterization has been reported 
(DaSilva et al 2009). A mouse monoclonal antibody against total AR (F39.4.1, Biogenex, 
San Ramon, CA) was used for immunoblotting. A polyclonal antibody against AR (C-19, 
Santa Cruz) was used for immunoprecipitation. The antibody against total Ack1 was 
described previously (Mahajan et al 2005). A phospho-specific antibody against Ack1 p-
Tyr-284 (# 09-142) was obtained from Millipore (Billerica, MA). Antibodies against total 
Src (#2108) and phospho-specific Src p-Tyr-416 (#2101) were obtained from Cell Signaling 
Technology (Beverly, MA).
Transfections and knockdown
293T cells and COS7 cells were transfected with AR or Ack1 or Src expression vectors 
using Effectene (Qiagen, Valencia, CA) according to the manufacturer's direction. siRNA 
sequences against Ack1 were previously described (Mahajan et al 2007). For knocking 
down Src, Validated Stealth RNAi™ siRNA against Src (Invitrogen, Carlsbad, CA) was 
used according to the manufacturer. LNCaP cells were transfected using siPort Lipid 
(Ambion, Austin, TX) with 100 nM of siRNA or negative control scrambled siRNA. After 
24 hrs, cells were treated with ligands as indicated. All experiments were repeated at least 
three times.
Proliferation Assays
LNCaP cells or LAPC-4 cells were seeded at a density of 104 cells per well in triplicate in a 
96-well plate in serum-free medium (RPMI 1640 for LNCaP and IMDM for LAPC-4). On 
day 0, cells were treated with DHT (10 nM), EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 
(100 ng/ml), bombesin (1 nM), or IL-6 (10 ng/ml). After 3 days of incubation, relative cell 
proliferation was measured using colorimetric dye WST-8 (Cell Counting Kit-8, Dojindo, 
Rockville, MD) according to the manufacturer's direction.
Reporter assays and quantitative RT-PCR
LNCaP cells (8 × 105 cells per 6-cm plate) were transfected with the ARR2-PB-luciferase 
reporter (500 ng) (Zhang et al 2000) along with the AR expression vector (50 ng), using 
Effectene, as described (Mahajan et al 2007). After overnight incubation, cells were pre-
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treated with dasatinib as indicated for 2 hrs, then EGF (100 ng/ml) or heregulin (10 ng/ml) 
for 20 hrs. Luciferase activity was determined, as described (Mahajan et al 2007). The IC50 
concentration of dasatinib required for inhibition of heregulin-driven luciferase activity was 
calculated using the dose-response variable slope (four parameters) function of the 
GraphPad Prism 5 software (GraphPad, La Jolla, CA). For measurement of PSA and hK2 
mRNA levels, LNCaP or LAPC-4 cells were incubated in serum-free medium and were pre-
treated with dasatinib (10 nM) for 2 hrs, then treated with heregulin (10 ng/ml) or EGF (100 
ng/ml) for 20 hrs. Total RNA was isolated and the mRNA levels of PSA and hK2 were 
determined by quantitative RT-PCR, as described (Mahajan et al 2007).
Colony formation in soft agar
LNCaP cells expressing Ack1 or vector control (104 cells per well) were suspended in 
0.45% Noble agar along with the indicated concentration of dasatinib and placed above a 
layer of solidified 0.9% Noble agar in 6 well plates in triplicates. After 3 weeks, colonies 
were visualized by staining with MTT.
Xenograft tumor growth
LNCaP cells stably expressing activated Ack1 by retroviral transduction have been 
described (Mahajan et al 2005). LNCaP-Ack1 cells (2 × 106) were mixed with an equal 
volume of Matrigel (BD Biosciences, Franklin Lakes, NJ) and implanted subcutaneously in 
the flank of castrated nude male mice, as described (Mahajan et al 2005, Mahajan et al 
2007). When tumors became palpable, mice were randomly divided into two groups. 
Dasatinib was dissolved in citrate buffer (80 mM, pH 3.1) and administered to mice via oral 
gavage at a dose of 30 mg/kg twice daily. Tumor size was measured with calipers twice per 
week. These procedures were approved by the Institutional Animal Use and Care 
Committee.
Statistical Methods
The nonparametric Wilcoxon rank-sum test (using Van der Waerden normal scores) was 
used for the two-group comparisons of tumor volumes of the treated group (n=8) to the 
control group (n=7) at days 25 and 29 of treatment. Exact nominal (unadjusted for multiple 
comparisons) two-sided p-values were reported. Statistical analyses were performed using 
SAS statistical software, Version 9.2 (SAS Institute, Inc., Cary, NC).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phospho-specific antibodies demonstrate that AR is phosphorylated at Tyr-267 and 
Tyr-534 after ligand stimulation
(A) 293T cells were transfected with the expression vector encoding wildtype AR or Y267F 
AR or Y534F AR along with constitutively active Ack1 or empty vector. After 24 hours, 
protein extracts were immunoblotted with the antibody specific for phospho-Y267 AR or 
total AR. (B) COS7 cells were transfected with the vector encoding wildtype AR or Y267F 
AR or Y534F AR along with constitutively active Ack1 or activated Src or empty vector, as 
indicated. After 24 hours, protein extracts were immunoprecipitated with the AR antibody, 
then immunoblotted with the antibody specific for phospho-Y267 AR or phospho-Y534 AR 
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or total AR, as indicated. (C) LNCaP cells were treated with EGF (100 ng/ml), heregulin (10 
ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml), or bombesin (1 nM) for 60 min. Protein extracts 
were immunoblotted with the antibody specific for phospho-Y267 AR or total AR. (D) 
LNCaP cells were treated as above. Protein extracts were immunoprecipitated with the AR 
antibody, then immunoblotted with the antibody specific for phospho-Y534 AR. Blots 
shown are representative of three independent experiments.
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Figure 2. EGF, heregulin, Gas6, bombesin, and IL-6 stimulate proliferation of androgen-
dependent prostate cancer cell lines in the absence of androgen
Cells were seeded in serum-free medium in triplicate wells of a 96-well plate and treated 
with EGF (100 ng/ml), heregulin (10 ng/ml), Gas6 (100 ng/ml), IL-6 (10 ng/ml), or 
bombesin (1 nM) for 72 hours. Relative cell proliferation was determined by addition of 
colorimetric dye WST-8 and measuring absorbance at 450 nM. (A) LNCaP cells. (B) 
LAPC-4 cells. Data shown are representative of three similar independent experiments. All 
treatment conditions are significantly different from untreated control with p <0.05 by t-test.
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Figure 3. Dasatinib inhibits Ack1 kinase activity and inhibits heregulin-induced AR 
phosphorylation at Tyr-267
(A) 293T cells were transfected with empty vector or kinase-dead Ack1 or constitutively 
active Ack1. After 24 hours, cells were treated with increasing concentrations of dasatinib 
for 2 hours. Protein extracts were immunoblotted with the antibody against phospho-Ack1 
or total Ack1. (B) LNCaP cells were pre-treated with dasatinib at increasing concentrations 
for 2 hours, then treated with heregulin (10 ng/ml) for 60 min. Protein extracts were 
immunoblotted with the antibody against phospho-Y267 AR or total AR or phospho-Ack1 
or total Ack1. Blots shown are representative of three independent experiments.
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Figure 4. Dasatinib inhibits EGF-induced AR phosphorylation at Tyr-534 but not Tyr-267
(A) LNCaP cells were pre-treated with dasatinib (10 nM) for 2 hours, then treated with EGF 
(100 ng/ml) for 60 or 90 min. Protein extracts were immunoprecipitated with the AR 
antibody, then immunoblotted with the antibody specific for phospho-Y534 AR or total AR. 
(B) LNCaP cells were pre-treated with dasatinib at increasing concentrations for 2 hours, 
then treated with EGF (100 ng/ml) for 60 min. Protein extracts were immunoblotted with the 
antibody against phospho-Y267 AR or total AR. (C, D) LNCaP cells were treated as above. 
Cells were also treated with heregulin (10 ng/ml) for 60 min as a positive control of Ack1 
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activation. Protein extracts were immunoblotted with the antibody against phospho-Ack1 or 
total Ack1 or phospho-Src or total Src. Blots shown are representative of three independent 
experiments.
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Figure 5. Knockdown of Src or Ack1 demonstrates the existence of an additional kinase that 
induces AR phosphorylation at Tyr-267 after EGF stimulation
LNCaP cells were transfected with control or Src-specific or Ack1-specific siRNA. After 24 
hours, cells were treated with heregulin, Gas6, EGF, IL-6, or bombesin, as indicated, for 60 
min. (A) Protein extracts were immunoblotted with the antibody specific for phospho-Y267 
AR or total AR. (B) Protein extracts were immunoprecipitated with the AR antibody, then 
immunoblotted with the antibody specific for phospho-Y534 AR. Protein extracts were also 
immunoblotted with the antibody specific for Src or Ack1. Blots shown are representative of 
at least three independent experiments.
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Figure 6. Dasatinib inhibits heregulin-induced AR activity, but not EGF-induced AR activity
(A, B) LNCaP cells were transfected with the AR reporter ARR2-PB-luciferase. After 
overnight incubation, cells were pre-treated with dasatinib for 2 hrs, then with heregulin (10 
ng/ml) (A) or EGF (100 ng/ml) (B) for 20 hrs. Cell extracts were assayed for luciferase 
activity. The mean and standard deviation of triplicate samples of a representative 
experiment are shown from three independent experiments with similar results. (C, D) 
LNCaP cells were pre-treated with dasatinib (10 nM) for 2 hrs, then with heregulin (10 
ng/ml) or EGF (100 ng/ml) for 20 hrs. RNA was isolated and quantitative RT-PCR was 
performed to determine the levels of PSA (C) or hK2 (D) mRNA. Data shown are 
representative of two independent experiments with similar results.
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Figure 7. Dasatinib inhibits anchorage-independent colony formation and xenograft tumor 
growth of LNCaP-Ack1 cells in castrated mice
(A) LNCaP-Ack1 cells and vector control cells were plated in soft agar with indicated 
concentrations of dasatinib in the top layer and incubated for 21 days. Colonies were stained 
and counted. The mean and standard deviation of triplicate wells of a representative 
experiment are shown from three independent experiments with similar results. (B) 
Castrated mice were implanted subcutaneously with LNCaP-Ack1 cells. When tumors 
became palpable, mice were treated with vehicle control (n=7) or dasatinib (n=8) via oral 
gavage at a dose of 30 mg/kg bid and the tumor volume was measured twice per week. (* 
Liu et al. Page 20













indicates p<0.04 and ** indicates p<0.009.) (C) Three independent tumors were harvested 
from mice given vehicle only or dasatinib at the conclusion of the experiment. Protein 
extracts were immunoblotted for expression of total Ack1, phospho-Ack1, total AR and 
phospho-Y267 AR.
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Figure 8. Model of AR phosphorylation by non-androgen ligands
Heregulin and Gas6 activate Ack1 kinase, which leads to AR Tyr-267 phosphorylation. 
EGF, bombesin, and IL-6 activate Src kinase, leading to AR Tyr-534 phosphorylation. 
Additionally, EGF activates an unidentified dasatinib-resistant tyrosine kinase that 
phosphorylates AR at Tyr-267.
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